LIN vs VIR · P/E 34, rev $33.99B vs rev $74.2M
Linde plc Ordinary Shares (LIN) versus Vir Biotechnology Inc (VIR) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Vir Biotechnology Inc (VIR) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported VIR revenue for 2024-12-31 was $74.2M. Net income was -$522.0M. Revenue was down 13.9% from 2023-12-31 to 2024-12-31. VIR currently screens at market cap $1.45B.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. VIR currently screens at market cap $1.45B.
Not investment advice. Open the LIN and VIR stock pages for the full models.
Not investment advice.